Toxoplasmosis in immunocompromised patients

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064211%3A_____%2F15%3A%230000463" target="_blank" >RIV/00064211:_____/15:#0000463 - isvavai.cz</a>

Result on the web

<a href="http://www.prolekare.cz/epidemiologie-clanek/toxoplasmoza-u-imunokompromitovanych-pacientu-52442" target="_blank" >http://www.prolekare.cz/epidemiologie-clanek/toxoplasmoza-u-imunokompromitovanych-pacientu-52442</a>

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Toxoplasmosis in immunocompromised patients

Original language description

In humans, toxoplasmosis mostly occurs as a latent infection, but in immunocompromised individuals, the agent may reactivate and cause severe to life-threatening disease. HIV positive individuals and transplant recipients, in particular hematopoietic stem cell transplant and heart transplant recipients, are at highest risk. The disease most often affects the central nervous system but can involve any organ. Because of the alteration of the immune response in these patients, the serodiagnosis is not reliable and direct detection of the causative agent is needed - namely by microscopy and DNA PCR. If inadequately treated or left untreated, toxoplasmosis generally has a fatal prognosis in immunocompromised patients and therefore, the treatment must be started as early and energetically as possible. The gold standard both in the treatment of reactivation and secondary prophylaxis is the pyrimethamine-sulfadiazine combination while co-trimoxazole can be used in the primary prophylaxis for high-risk patients.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FN - Epidemiology, infection diseases and clinical immunology

OECD FORD branch

—

Project

<a href="/en/project/NT11429" target="_blank" >NT11429: Effect of long-term asymptomatic Toxoplasma gondii infection on the immune and clinical state of HIV-positive patients</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2015

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

EPIDEMIOLOGIE MIKROBIOLOGIE IMUNOLOGIE

ISSN

1210-7913

e-ISSN

—

Volume of the periodical

64

Issue of the periodical within the volume

2

Country of publishing house

CZ - CZECH REPUBLIC

Number of pages

7

Pages from-to

59-65

UT code for WoS article

000362267300001

EID of the result in the Scopus database

—